A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.
Valerie CuvierUlrike LorchStephan WitteAurelie OlivierSebastien GibotIsabelle DelorJean-Jacques GaraudMarc DeriveMargarita Salcedo-MagguilliPublished in: British journal of clinical pharmacology (2018)
The novel immunomodulator nangibotide displayed favourable safety and PK profiles at all doses, including expected pharmacologically active doses, and warrants further clinical development.